Bliss Kaneshiro1, Alison Edelman2, Chandravanu Dash3, Jui Pandhare3, Faapisa M Soli4, Jeffrey T Jensen2. 1. John A. Burns School of Medicine, University of Hawaii at Manoa, 1319 Punahou Street, Suite 824, Honolulu, HI 96826, USA. Electronic address: blissk@hawaii.edu. 2. Oregon Health & Science University, 3181 SW Sam Jackson Park Road, UHN 50, Portland, OR 97239, USA. 3. Meharry Medical College, 1005 Dr. D. B. Todd Jr. Boulevard, Suite 5131, Nashville, TN 37208, USA. 4. RMATRIX, John A. Burns School of Medicine, University of Hawaii at Manoa, 651 Ilalo Street, Medical Education Building, Office of the Dean, 2nd Floor, Honolulu, HI 96813, USA.
Abstract
OBJECTIVES: To describe the effect of combined oral contraceptives (COCs) on matrix metalloproteinases MMP-2 and MMP-9 activity and compare MMP activity in women taking a COC with or withoutdoxycycline. STUDY DESIGN: Subjects (n=20) underwent endometrial biopsies (1) in the late luteal phase of a baseline cycle prior to initiating COCs, (2) on days 19-21 while taking COCs in a standard 28-day cycle (7-day hormone-free interval) and (3) on days 26-28 while taking active COCs continuously for a 28-day cycle. During the continuous COC cycle, they were randomized to receive daily subantimicrobial dose doxycycline 40mg or placebo. RESULTS: Compared to baseline, COC treatment increased MMP-2 (p<.001) and MMP-9 (p<.001). MMP activity was lower in subjects taking a COC with doxycycline compared to those receiving placebo although only significantly lower for MMP-2 latent form (p=.002). CONCLUSIONS:Unscheduled bleeding with COCs may be the result of increased endometrial MMPs. Sample size limitations prevent us from determining how doxycycline affects MMP activity in COC users.
RCT Entities:
OBJECTIVES: To describe the effect of combined oral contraceptives (COCs) on matrix metalloproteinases MMP-2 and MMP-9 activity and compare MMP activity in women taking a COC with or without doxycycline. STUDY DESIGN: Subjects (n=20) underwent endometrial biopsies (1) in the late luteal phase of a baseline cycle prior to initiating COCs, (2) on days 19-21 while taking COCs in a standard 28-day cycle (7-day hormone-free interval) and (3) on days 26-28 while taking active COCs continuously for a 28-day cycle. During the continuous COC cycle, they were randomized to receive daily subantimicrobial dose doxycycline 40mg or placebo. RESULTS: Compared to baseline, COC treatment increased MMP-2 (p<.001) and MMP-9 (p<.001). MMP activity was lower in subjects taking a COC with doxycycline compared to those receiving placebo although only significantly lower for MMP-2 latent form (p=.002). CONCLUSIONS: Unscheduled bleeding with COCs may be the result of increased endometrial MMPs. Sample size limitations prevent us from determining how doxycycline affects MMP activity in COC users.
Authors: David F Archer; Jeffrey T Jensen; Julia V Johnson; Hannah Borisute; Gary S Grubb; Ginger D Constantine Journal: Contraception Date: 2006-09-18 Impact factor: 3.375
Authors: Shumei Zhao; Chainarong Choksuchat; Yueqin Zhao; Susan A Ballagh; George A Kovalevsky; David F Archer Journal: Contraception Date: 2009-02-07 Impact factor: 3.375